


Intervacc signs agreement for optimization of manufacturing

Intervacc is pleased to announce that an agreement has now been signed with PX' Therapeutics, Grenoble, France, for process optimization of Strangvac. PX' Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the experience, facilities and personnel to produce recombinant proteins from E. coli in compliance with GMP.

The aim is to obtain a more efficient and cost effective production of Strangvac®, which is composed of three recombinant proteins. Initial work on optimization has already begun and Intervacc foresees a smooth transfer of production technology and analytical procedures associated with the manufacturing process.



Date Created
2015-10-28